Wadhwani, Harshal et al. published their research in International Journal of Pharmacy and Pharmaceutical Research in 2021 | CAS: 145040-37-5

1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.Recommanded Product: 145040-37-5

Formulation development of oral liquisolid systems of poorly water-soluble drug, hydrochlorothiazide, using mixed solvency concept and their evaluations was written by Wadhwani, Harshal;Maheshwari, R. K.. And the article was included in International Journal of Pharmacy and Pharmaceutical Research in 2021.Recommanded Product: 145040-37-5 This article mentions the following:

The present work is aimed to enhance the drug loading capacity in a liquisolid system, decreasing the required volume of nonvolatile solvent due to enhanced solubility of a drug in nonvolatile solvent using the mixed solvency concept. Hydrochlorothiazide was selected as a model poorly water-soluble drug for exploring the mixed solvency concept to enhance the solubility and hence to enhance the release rate of the drug. The proposed formulation is aimed to enhance the solubility of hydrochlorothiazide by employing the mixed solvency concept and to develop the fast-release capsule of hydrochlorothiazide using the liquisolid technique. The prepared liquisolid dosage form was tested for flow properties, thin layer chromatog., drug excipient interaction studies, drug content determination, disintegration time study, and dissolution studies. The comparative dissolution studies were performed and it was observed that the formulated capsule containing liquisolid formulation released 81.09% of the drug within 10 min, and only 56.25% drug was released from the marketed tablet formulation within 10 min. In the experiment, the researchers used many compounds, for example, 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5Recommanded Product: 145040-37-5).

1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.Recommanded Product: 145040-37-5

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem